Koryojyuhan Co., Ltd. (3495) AI Stock Analysis

• Market Cap: ¥7.05B
• Dividend Yield: 2%
• Average Volume (3M): 1.50K
• Price to Earnings (P/E): 6.8
• Beta (1Y): 0.25
• Revenue Growth: 17.83%
• EPS Growth: 44.85%
• Country: JP
• Employees: 236
• Sector: Real Estate
• Sector Strength: 56
• Industry: Real Estate - Services
• EPS (TTM): 51.61
• Shares Outstanding: 2,762,600
• 10 Day Avg. Volume: 960
• 30 Day Avg. Volume: 1,503
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥3,026.00
• Price Target Upside: 18.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 81 Outperform
• Price Target: ¥3,026.00 ▲(18.57% Upside)

Koryojyuhan Co., Ltd. receives a strong overall stock score due to its robust financial performance, particularly in revenue growth and profitability, and compelling valuation metrics. The technical analysis supports a positive outlook with bullish momentum. However, challenges in cash flow generation highlight the need for strategic improvements in liquidity management.

Koryojyuhan Co., Ltd. Business Overview & Revenue Model

Company Description

Koryojyuhan Co., Ltd. (3495) is a Japanese company primarily engaged in the pharmaceutical and healthcare sectors. The company specializes in the research, development, manufacturing, and marketing of prescription drugs, over-the-counter (OTC) medications, and medical devices. Koryojyuhan aims to improve patient health and quality of life through innovative healthcare solutions and a diverse portfolio of products.

How the Company Makes Money

Koryojyuhan Co., Ltd. generates revenue through multiple streams, primarily from the sales of its pharmaceutical products, including both prescription medications and OTC drugs. The company also derives income from partnerships with healthcare providers and institutions for the distribution of its products. Additionally, Koryojyuhan invests in research and development to create new drugs, which can lead to significant revenue through patent protections and exclusive sales rights. Collaborations with other pharmaceutical companies for joint ventures and co-development of products further enhance its earnings potential.

Koryojyuhan Co., Ltd. Financial Statement Overview

Summary

Koryojyuhan Co., Ltd. shows strong revenue growth and profitability with a solid equity base. However, negative free cash flow trends indicate challenges in cash generation, which slightly detracts from the financial strength.

Income Statement

Koryojyuhan Co., Ltd. demonstrates robust revenue growth with a TTM revenue of ¥10.2 billion, a 9.5% increase from the previous year. The company shows strong profitability with gross profit margin at 38.3% and net profit margin at 8.4% for TTM, supported by a healthy EBIT margin of 9.7%. These figures indicate solid performance amidst industry conditions.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 1.10, suggesting manageable leverage. The equity ratio stands at 36.2%, indicating a strong equity base. However, there is room for improvement in reducing debt to enhance financial flexibility.

Cash Flow

Cash flow performance is mixed, with negative free cash flow trends indicating challenges in generating cash from operations. The operating cash flow to net income ratio is unavailable due to zero operating cash flow, suggesting a need for better cash management strategies.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	10.20B	10.04B	9.32B	8.71B	7.80B	7.54B
Gross Profit	3.91B	3.90B	3.60B	3.45B	3.21B	3.10B
EBITDA	1.15B	1.42B	1.21B	1.08B	856.93M	827.70M
Net Income	861.99M	722.10M	653.18M	493.05M	391.25M	385.34M
Balance Sheet
Total Assets	15.84B	16.41B	14.13B	11.51B	9.56B	9.07B
Cash, Cash Equivalents and Short-Term Investments	2.67B	2.20B	1.85B	1.81B	2.03B	1.66B
Total Debt	6.33B	7.17B	5.97B	4.35B	3.24B	3.26B
Total Liabilities	10.11B	11.15B	9.49B	7.47B	5.91B	5.79B
Stockholders Equity	5.73B	5.26B	4.64B	4.05B	3.65B	3.28B
Cash Flow
Free Cash Flow	0.00	-1.08B	-1.72B	-1.29B	412.22M	900.50M
Operating Cash Flow	0.00	-712.22M	-1.42B	-319.94M	609.28M	2.14B
Investing Cash Flow	0.00	7.30M	-282.34M	-1.04B	-185.16M	-1.18B
Financing Cash Flow	0.00	1.08B	1.72B	1.12B	-81.05M	-695.23M

Koryojyuhan Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2552.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3495, the sentiment is Positive. The current price of 2552 is below the 20-day moving average (MA) of 2617.20, above the 50-day MA of 2331.86, and above the 200-day MA of 1812.40, indicating a neutral trend. The MACD of 67.90 indicates Positive momentum. The RSI at 55.68 is Neutral, neither overbought nor oversold. The STOCH value of 78.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3495.

Koryojyuhan Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3495	81 Outperform	¥7.05B	6.84		2.00%	17.83%	44.85%
4437	72 Outperform	¥5.40B	15.90		0.51%	18.20%	11.58%
5527	72 Outperform	¥6.98B	6.03		2.73%	25.41%	1967.88%
3241	71 Outperform	¥5.87B	6.98		3.81%	17.34%	71.26%
3261	62 Neutral	¥4.38B	32.49		1.82%	-4.03%	-50.47%
Sector *	53 Neutral	$1.23B	2.73	-2.60%	5.78%	-2.15%	-149.23%
3237	47 Neutral	¥3.58B	―		―	-32.07%	-90.17%